From: Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers
n (%)
Total patients
9 (13.2%)
Injection-site reactions
2 (2.9%)
Constipation
5 (7.4%)
Blood pressure elevation (20 mmHg <)
1 (1.5%)
Alopecia
Diarrhea